Augustine Therapeutics
PrivateLast Round
Series A
Mar 24, 2025
Total Funding Raised
$108.08M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Augustine Therapeutics operates in Healthcare & Life Sciences and is based in Leuven. Its latest recorded funding round was a Series A round in March 2025.
Augustine Therapeutics is a biotechnology company that develops therapeutic drugs designed to treat neuromuscular and neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Augustine Therapeutics Comparables
Compare Augustine Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Regenacy Pharmaceuticals | 87% | |
| Eikonizo Therapeutics | 85% | |
| HDAX Therapeutics | 83% |
For institutional investors. Book with your work email.
Augustine Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 24, 2025 | ||||
| Series A | Jun 26, 2024 | ||||
| Seed | Feb 26, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Augustine Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Asabys Partners | Series A |
| Newton Biocapital | Series A |
| KU Leuven Research & Development (LRD) | Seed, Series A |
| V-Bio Ventures | Series A, Seed |
| Novo Holdings | Series A |
| PMV | Seed, Series A |
| VIB | Seed, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased from 0 to 6, representing 25% of headcount.
- Jan 20, 2026
Monthly visitors grew 406% MoM, reaching 3.1K.
For institutional investors. Book with your work email.
Augustine Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Augustine Therapeutics's valuation, stock price, and market status.
Is Augustine Therapeutics a public or private company?
Augustine Therapeutics is a private company.
What is the current stock price of Augustine Therapeutics?
Augustine Therapeutics is a private company, so its shares have no public market price. Caplight tracks Augustine Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Augustine Therapeutics worth (valuation)?
Valuation information for Augustine Therapeutics is not publicly available.
Can I buy Augustine Therapeutics stock?
Augustine Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Augustine Therapeutics's last funding round?
Augustine Therapeutics's most recent funding round was Series A on March 24, 2025.
Who are the main investors in Augustine Therapeutics?
Key investors in Augustine Therapeutics include Asabys Partners, V-Bio Ventures, Novo Holdings, Jeito Capital.
Will Augustine Therapeutics IPO soon?
No public IPO plans have been announced for Augustine Therapeutics.
How can I track Augustine Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Augustine Therapeutics's shares on secondary markets.